FDA Approves Generic HIV Prevention Shot, Expanding Access for Lower-Income Countries

The U.S. Food and Drug Administration has approved a generic version of a long-acting injectable HIV prevention drug, a move that could significantly lower costs and improve access in lower-income countries. The approval follows a push by global health organizations to make pre-exposure prophylaxis (PrEP) more affordable and available outside high-income nations. The generic version of the drug, which is administered every two months, has been shown to be highly effective at preventing HIV infection. By allowing generic manufacturing, the FDA decision enables procurement by major global health programs such as PEPFAR and the Global Fund, which supply medicines to countries with high HIV burdens. This step is expected to increase competition, reduce prices, and enable scale-up of HIV prevention efforts in regions like sub-Saharan Africa, where the epidemic remains concentrated. The approval marks a pivotal moment in the fight against HIV, as injectable PrEP offers a discreet alternative to daily pills, potentially improving adherence and uptake among at-risk populations. As generic production ramps up, millions more people could gain access to a powerful tool to prevent new infections.